WO2006034337A3 - Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus - Google Patents
Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus Download PDFInfo
- Publication number
- WO2006034337A3 WO2006034337A3 PCT/US2005/033803 US2005033803W WO2006034337A3 WO 2006034337 A3 WO2006034337 A3 WO 2006034337A3 US 2005033803 W US2005033803 W US 2005033803W WO 2006034337 A3 WO2006034337 A3 WO 2006034337A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hepatitis
- cyclopentaindole
- carbazole
- virus
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0515596-7A BRPI0515596A (en) | 2004-09-23 | 2005-09-21 | pharmaceutical composition used for the treatment and / or prevention of hcv, and methods of inhibiting hepatitis c polymerase ns5b from treating or preventing hepatitis c infection in a mammal |
JP2007533604A JP2008514611A (en) | 2004-09-23 | 2005-09-21 | Derivatives of carbazole and cyclopentaindole for treating infection with hepatitis C virus |
AU2005286727A AU2005286727A1 (en) | 2004-09-23 | 2005-09-21 | Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus |
EP05815334A EP1793819A2 (en) | 2004-09-23 | 2005-09-21 | Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus |
CA002577413A CA2577413A1 (en) | 2004-09-23 | 2005-09-21 | Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus |
MX2007003371A MX2007003371A (en) | 2004-09-23 | 2005-09-21 | Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61214404P | 2004-09-23 | 2004-09-23 | |
US60/612,144 | 2004-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006034337A2 WO2006034337A2 (en) | 2006-03-30 |
WO2006034337A3 true WO2006034337A3 (en) | 2006-09-14 |
Family
ID=35907017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/033803 WO2006034337A2 (en) | 2004-09-23 | 2005-09-21 | Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus |
Country Status (9)
Country | Link |
---|---|
US (1) | US7250441B2 (en) |
EP (1) | EP1793819A2 (en) |
JP (1) | JP2008514611A (en) |
CN (1) | CN101035528A (en) |
AU (1) | AU2005286727A1 (en) |
BR (1) | BRPI0515596A (en) |
CA (1) | CA2577413A1 (en) |
MX (1) | MX2007003371A (en) |
WO (1) | WO2006034337A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9108969B2 (en) | 2008-08-27 | 2015-08-18 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US9126932B2 (en) | 2008-07-23 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US9175320B2 (en) | 2010-01-27 | 2015-11-03 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof |
US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
US11566026B2 (en) | 2016-12-22 | 2023-01-31 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006121467A2 (en) * | 2004-11-22 | 2006-11-16 | Smithkline Beecham Corporation | Tetrahydrocarbazole derivatives for treating flaviridae viruses |
AR058053A1 (en) | 2005-09-19 | 2008-01-23 | Toole Doris C O | CRYSTALLINE FORMS POLYMORPHICS OF ACID DIODIUM SALT N- (5-CHLOROSALICILOIL) -8- AMINOCAPRILICO |
WO2008024763A2 (en) * | 2006-08-25 | 2008-02-28 | Wyeth | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
AU2007339386B8 (en) | 2006-12-22 | 2013-12-05 | Merck Sharp & Dohme Corp. | 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections |
CN101631773A (en) | 2006-12-22 | 2010-01-20 | 先灵公司 | 4 of treatment or prevention HCV and related viral infections, the 5-ring annulated indole derivatives |
WO2008136815A2 (en) | 2006-12-22 | 2008-11-13 | Schering Corporation | 5, 6-ring annulated indole derivatives and use thereof |
ES2381410T3 (en) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Combination therapy for the treatment of HCV infections |
AU2008295483B2 (en) * | 2007-08-29 | 2013-11-21 | Merck Sharp & Dohme Corp. | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
BRPI0816116A2 (en) | 2007-08-29 | 2015-03-03 | Schering Corp | 2,3-SUBSTITUTED INDOL DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS. |
CN101821252A (en) | 2007-08-29 | 2010-09-01 | 先灵公司 | The indole derivatives and the using method thereof that replace |
TW200911807A (en) | 2007-08-29 | 2009-03-16 | Schering Corp | 2,3-substituted azaindole derivatives and methods of use thereof |
KR101396696B1 (en) * | 2007-10-10 | 2014-05-16 | 노파르티스 아게 | Spiropyrrolidines and their use against hcv and hiv infection |
JP5249344B2 (en) | 2007-11-16 | 2013-07-31 | メルク・シャープ・アンド・ドーム・コーポレーション | Indole derivatives substituted at the 3-position of the heterocyclic ring and use thereof |
CA2705587A1 (en) | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-aminosulfonyl substituted indole derivatives and methods of use thereof |
EP2303893B1 (en) | 2008-06-13 | 2016-12-07 | Merck Sharp & Dohme Corp. | Tricyclic indole derivatives |
ES2443948T3 (en) | 2008-12-19 | 2014-02-21 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
SG10201501575VA (en) | 2010-03-03 | 2015-04-29 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
CN105566202B (en) * | 2014-10-31 | 2018-06-22 | 华东师范大学 | A kind of 1,2,3,4- tetrahydro cyclopentyl base indole derivatives and its synthetic method |
CN116850181A (en) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | Treatment and S1P 1 Methods of receptor-related disorders |
ES2929526T3 (en) | 2015-06-22 | 2022-11-29 | Arena Pharm Inc | (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl) acid L-arginine crystal salt acetic acid for use in disorders associated with the S1P1 receptor |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP4141002A1 (en) | 2015-11-19 | 2023-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PL3394033T3 (en) | 2015-12-22 | 2021-05-31 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
TW201808950A (en) | 2016-05-06 | 2018-03-16 | 英塞特公司 | Heterocyclic compounds as immunomodulators |
MA45116A (en) | 2016-05-26 | 2021-06-02 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS |
MX2018016273A (en) | 2016-06-20 | 2019-07-04 | Incyte Corp | Heterocyclic compounds as immunomodulators. |
EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (en) | 2016-08-29 | 2021-04-28 | Incyte Corp | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS |
ES2899402T3 (en) | 2016-12-22 | 2022-03-11 | Incyte Corp | Pyridine derivatives as immunomodulators |
CN110582493B (en) | 2016-12-22 | 2024-03-08 | 因赛特公司 | Benzoxazole derivatives as immunomodulators |
CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
MA47504A (en) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS |
SG11202009440WA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
DK3790877T3 (en) | 2018-05-11 | 2023-04-24 | Incyte Corp | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNE MODULATORS |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
TW202120504A (en) | 2019-11-11 | 2021-06-01 | 美商英塞特公司 | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
TW202233615A (en) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Crystalline form of a pd-1/pd-l1 inhibitor |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
AU2021373044A1 (en) | 2020-11-06 | 2023-06-08 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307077A1 (en) * | 1987-07-21 | 1989-03-15 | Merck Frosst Canada Inc. | Tetrahydrocarbazoles for the improvement of cyclosporin therapy |
WO1998038986A2 (en) * | 1997-03-06 | 1998-09-11 | Roche Diagnostics Gmbh | Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections |
US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
WO2005072408A2 (en) * | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc | Treating a viral disorder |
-
2005
- 2005-09-21 WO PCT/US2005/033803 patent/WO2006034337A2/en active Application Filing
- 2005-09-21 JP JP2007533604A patent/JP2008514611A/en not_active Withdrawn
- 2005-09-21 EP EP05815334A patent/EP1793819A2/en not_active Withdrawn
- 2005-09-21 MX MX2007003371A patent/MX2007003371A/en not_active Application Discontinuation
- 2005-09-21 BR BRPI0515596-7A patent/BRPI0515596A/en not_active IP Right Cessation
- 2005-09-21 AU AU2005286727A patent/AU2005286727A1/en not_active Abandoned
- 2005-09-21 US US11/230,729 patent/US7250441B2/en not_active Expired - Fee Related
- 2005-09-21 CA CA002577413A patent/CA2577413A1/en not_active Abandoned
- 2005-09-21 CN CNA2005800316732A patent/CN101035528A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0307077A1 (en) * | 1987-07-21 | 1989-03-15 | Merck Frosst Canada Inc. | Tetrahydrocarbazoles for the improvement of cyclosporin therapy |
US5830911A (en) * | 1996-08-14 | 1998-11-03 | American Home Products Corporation | Pyranoindole and tetrahydrocarbazole inhibitors of COX-2 |
WO1998038986A2 (en) * | 1997-03-06 | 1998-09-11 | Roche Diagnostics Gmbh | Use of carvedilol or derivatives thereof for the manufacture of a medicament for the prevention and treatment of viral infections |
WO2005072408A2 (en) * | 2004-01-29 | 2005-08-11 | Elixir Pharmaceuticals, Inc | Treating a viral disorder |
Non-Patent Citations (2)
Title |
---|
GOPALSAMY ARIAMALA ET AL: "Identification of carbazole and cyclopentaindole derivatives as inhibitors of HCV RNA dependent RNA polymerase.", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 229, no. Part 2, March 2005 (2005-03-01), & 229TH NATIONAL MEETING OF THE AMERICAN-CHEMICAL-SOCIETY; SAN DIEGO, CA, USA; MARCH 13 -17, 2005, pages U167, XP008065271, ISSN: 0065-7727 * |
RAJ K ET AL: "NU- & OMICRON-DIALKYLAMINOALKYLCARBAXOLES AS POTENTIAL ANTIVIRAL AGENTS", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL. MEDICINAL, PUBLICATIONS & INFORMATIONS DIRECTORATE, NEW DELHI, IN, vol. 14B, no. 5, 1 May 1976 (1976-05-01), pages 371 - 373, XP000196847, ISSN: 0019-5103 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9126932B2 (en) | 2008-07-23 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US9522133B2 (en) | 2008-07-23 | 2016-12-20 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
US9108969B2 (en) | 2008-08-27 | 2015-08-18 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US9175320B2 (en) | 2010-01-27 | 2015-11-03 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof |
US9447041B2 (en) | 2010-01-27 | 2016-09-20 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof |
US11566026B2 (en) | 2016-12-22 | 2023-01-31 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US11555015B2 (en) | 2018-09-06 | 2023-01-17 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Also Published As
Publication number | Publication date |
---|---|
AU2005286727A1 (en) | 2006-03-30 |
EP1793819A2 (en) | 2007-06-13 |
CN101035528A (en) | 2007-09-12 |
JP2008514611A (en) | 2008-05-08 |
US20060063821A1 (en) | 2006-03-23 |
CA2577413A1 (en) | 2006-03-30 |
BRPI0515596A (en) | 2008-07-29 |
US7250441B2 (en) | 2007-07-31 |
WO2006034337A2 (en) | 2006-03-30 |
MX2007003371A (en) | 2007-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006034337A3 (en) | Carbazole and cyclopentaindole derivatives to treat infection with hepatitis c virus | |
WO2007092888A3 (en) | Hcv ns5b inhibitors | |
WO2008021745A3 (en) | Hepatitis c virus entry inhibitors | |
WO2007070556A3 (en) | N-(6-membered aromatic ring)-amido anti-viral compounds | |
WO2007019397A3 (en) | 6-membered aryl and heteroaryl derivatives for the treatment of hepatitis c virus | |
WO2007070600A3 (en) | N-(5-membered heteroaromatic ring)-amido anti-viral compounds | |
WO2010030538A3 (en) | Compounds for the treatment of hepatitis c | |
ATE469155T1 (en) | CYCLOPROPYL-FUSIONED INDOLEBENZAZEPINE HCV NS5B INHIBITORS | |
WO2008021927A3 (en) | Hepatitis c virus inhibitors | |
WO2009029384A3 (en) | Compounds for the treatment of hepatitis c | |
WO2004110351A3 (en) | Heterocyclic compounds for treating hepatitis c virus | |
WO2008021936A3 (en) | Hepatitis c virus inhibitors | |
NO20081846L (en) | Biphenyl derivatives and their use in the treatment of hepatitis C | |
MX2009006877A (en) | 5, 6-ring annulated indole derivatives and use thereof. | |
CY1113038T1 (en) | TRIETERCYCLIC UNITS, COMPOSITIONS, AND METHODS FOR CANCER TREATMENT | |
TW200745120A (en) | Indolobenzazepine HCV NS5B inhibitors | |
EA200800932A1 (en) | MODIFIED 4`-NUCLEOSIDE AS ANTI-VIRUS AGENTS | |
EA201170241A1 (en) | MACROCYCLIC KHINOXALINE COMPOUNDS AS HCV PROTEASE INHIBITORS NS3 INHIBITORS | |
NO20070194L (en) | Methods for the treatment of hepatitis C | |
TW200728317A (en) | Macrocylic inhibitors of hepatitis C virus | |
WO2006027628A3 (en) | Naphthalimide derivatives as antiviral agents | |
ATE533771T1 (en) | CYCLOPROPYL-CONDENSED INDOLOBENZAZEPINES AS HCV-NS5B INHIBITORS | |
WO2010055164A3 (en) | Isoquinolone derivatives as inhibitors of plavivirus replication | |
WO2009148961A3 (en) | Drugs to prevent hpv infection | |
DE602008006257D1 (en) | CYCLOPROPYL-CONDENSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2577413 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005815334 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580031673.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/003371 Country of ref document: MX Ref document number: 2007533604 Country of ref document: JP Ref document number: 2005286727 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005286727 Country of ref document: AU Date of ref document: 20050921 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005286727 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005815334 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0515596 Country of ref document: BR |